| 2026-08-14 | Deck | Corporate Presentation August 2026 |
| 2026-08-10 | Press release | Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results |
| 2026-08-10 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-10 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-07 | Press release | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-07-10 | Press release | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-07-09 | Press release | Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner |
| 2026-07-09 | 8-K | Form 8-K, Item 5.02 |
| 2026-07-07 | Press release | Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy |
| 2026-07-07 | 8-K | Form 8-K, Item 8.01 |
| 2026-06-05 | Deck | ORIGIN 3: Subgroup Analysis of a Phase 3 Trial of Atacicept in IgA Nephropathy |
| 2026-06-05 | Press release | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-02 | Press release | Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy |
| 2026-06-02 | 8-K | Form 8-K, Item 8.01 |
| 2026-05-26 | 8-K | Form 8-K, Item 5.07 |
| 2026-05-08 | Press release | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-05-07 | Press release | Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results |
| 2026-05-07 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-07 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-10 | Press release | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-04-09 | Proxy | Definitive proxy statement |
| 2026-03-27 | Press release | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-03-09 | 8-K | Form 8-K, Item 5.02 |
| 2026-02-26 | Press release | Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results |
| 2026-02-26 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-26 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-24 | Press release | Vera Therapeutics to Participate at Upcoming Investor Conferences |
| 2026-01-08 | Press release | Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference |
| 2026-01-07 | Press release | Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy |
| 2025-12-18 | 8-K | Form 8-K, Item 5.02 |
| 2025-12-10 | 8-K | Form 8-K, Item 8.01 |
| 2025-11-26 | 8-K | Form 8-K, Item 5.02 |
| 2025-11-06 | Deck | ORIGIN Phase 3 Update |
| 2025-11-06 | 8-K | Form 8-K, Item 8.01 |
| 2025-11-05 | 8-K | Form 8-K, Item 2.02 results |
| 2025-11-05 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-08-05 | 8-K | Form 8-K, Item 2.02 results |
| 2025-08-05 | 8-K | Form 8-K, Item 1.01 |
| 2025-08-05 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2025-06-03 | 8-K | Form 8-K, Item 1.01 |